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During pharmaceutical development, researchers might
spend substantial time and effort on a candidate com-
pound that has the desired effect on a protein target
only to find out that it does not have the desired
outcome on the whole body. To potentially avoid this
type of dead end, one can start with a natural experiment
to decide whether a particular biomarker is a good
target for drug development. In a recent example of
this approach, two groups used natural outliers for
a biomarker of interest to explore its outcome. These
population-based studies focused on apolipoprotein
C3 (ApoC3), which inhibits hydrolysis of triglyceride-
containing lipoproteins and thereby increases plasma tri-
glyceride levels. Rare genetic variation that lowers ApoC3
functionality would thus be expected to reduce triglycer-
ide levels. Although an association between triglyceride
levels and cardiovascular disease was already known,
these groups wanted to see whether a lifetime of low
triglyceride levels would translate into a lower risk of
cardiovascular disease. Both studies found a similar 40%
reduction in risk in groups of individuals heterozygous
for one of four APOC3 alleles with reduced function.
This natural experiment makes ApoC3 a plausible phar-
macological target for reducing risk of heart disease.
In fact, antisense oligonucleotides to APOC3 are being
explored for this purpose.
The TG and HDL Working Group of the Exome Sequencing
Project, National Heart, Lung, and Blood Institute. (2014).
N. Engl. J. Med. 371, 22–31.
Jorgensen et al. (2014). N. Engl. J. Med. 371, 32–41.
Mixed Up
In each human cell, hundreds of copies of the mtDNA
sequence are present, and they are not necessarily
identical. This phenomenon of a mixture of sequences,
known as heteroplasmy, contributes to the unique inher-
itance of mtDNA variation and makes it difficult to pre-
cisely predict the inheritance of mitochondrial disease.
Beyond these affected families, there are limited data for
estimating the prevalence of heteroplasmy, but recent
studies suggest that it might be widespread in the general
human population. This is borne out in the recent work
by Ye et al., who used sequence data on more than
1,000 individuals from the 1000 Genomes Project. They
report that 90% of this population has detectable hetero-1Department of Human Genetics, Emory University School of Medicine, Atlan
*Correspondence: kgarber@genetics.emory.edu
http://dx.doi.org/10.1016/j.ajhg.2014.07.010. 2014 by The American Societ
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plasmy, sequences are in a ratio as high as 90/10 in 44%
of the sample. Disease-associated sites in mtDNA are over-
represented in this heteroplasmy and seem to be subject
to purifying selection. However, selection is less efficient
than it would be on nuclear genetic variation, so it does
not effectively remove disease-associated variation. As
cells divide over a lifetime, the level of heteroplasmy
could shift toward pathogenic variation, and the authors
wonder whether this has the potential to contribute to
age-related diseases.
Ye et al. (2014). Proc. Natl. Acad. Sci. USA. Published online
July 7, 2014. http://dx.doi.org/10.1073/pnas.1403521111.
Do We Have the Power?
Is one mutation like any other? That is, is the disease risk
conferred by any pathogenic variant the same as that
conferred by any other in the same gene? Biologically,
this is not universally true because there can be a range
of activity from null to normal for a gene product. Practi-
cally, however, we almost always lump together all patho-
genic variation in the same gene and assign it the same
level of disease risk. Through a series of power calculations,
Shirts et al. considered the feasibility of instead examining
each variant individually. This allowed them to estimate
the sample sizes needed for classifying rare variation in
cancer genes and accurately estimating relative risk associ-
ated with these individual variants.With population-based
strategies, tens of thousands to millions of subjects will be
needed for classifying cancer variants. Required sample
sizes are much lower for family-based strategies, but these
would hinge on the ability to recruit the right individuals.
Their results leave Shirts et al. to conclude that much of
this rare missense variation will remain unclassified in
the near term.
Shirts et al. (2014). Genet. Med. 16, 529–534.
Forward and Back
Lacking some of the mechanisms that eukaryotic cells use
to generate diversity, some viruses use ribosomal frame-
shifting to produce alternate protein domains. The same
type of mechanism in higher eukaryotes hasn’t been
documented but—on the basis of what we know from
frameshift mutations—would instead be likely to result
in nonsense-mediated decay when a premature stop
codon is encountered in the 1 reading frame. Thista, GA 30322, USA
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prediction is borne out in work by Belew et al., who docu-
ment so-called programmed ribosomal frameshift (PRF)
events in CCR5, a gene most famous for encoding an
HIV coreceptor. CCR5 was a likely candidate for PRF on
the basis of the juxtaposition of a homopolymeric
sequence on which the ribosome could slip and a
sequence that would be predicted to form a complicated
RNA secondary structure. In cell culture, placing this
sequence upstream of a reporter gene put in a 1 frame
led to reporter expression with an efficiency of approxi-
mately 10%. The PRF mechanism is stimulated by a
miRNA that interacts with the CCR5 PRF signal sequence,
forming a triplex structure. As expected, shifting the
reading frame resulted in decreased CCR5 and its mRNA
via nonsense-mediated decay. Additional experiments
suggest that PRF also occurs on other cytokine receptors,
but how widespread this novel mechanism of gene regu-
lation is in mammals is still unclear.
Belew et al. (2014). Nature. Published online July 9, 2014.
http://dx.doi.org/10.1038/nature13429.130 The American Journal of Human Genetics 95, 129–130, August 7AVulnerable Gene
Haploinsufficiency for any of a number of genes that
encode ribosomal proteins causes Diamond-Blackfan ane-
mia (DBA). How a defect in a crucial cellular process leads
to a phenotype that is largely limited to erythrocytes has
puzzled researchers. The first clue came when mutations
in the gene encoding the transcription factor GATA1were
found in a small number of individuals who had been clin-
ically diagnosed with DBA. Ludwig et al. used these indi-
viduals to understand the relationship between protein
translation and GATA1. They discovered that this gene is
particularly sensitive to reduced ribosome abundance,
probably because of its highly structured 50 UTR. As such,
typical DBA-causing mutations result in reduced GATA1
levels and a downstream reduction in the expression of
GATA1 target genes. Expressing GATA1 in bone marrow
cells from these individuals increases production and dif-
ferentiation of erythroid cells, so it appears that this is a
major downstream contributor to the DBA phenotype.
Ludwig et al. (2014). Nat Med. 20, 748–753.This Month in Our Sister JournalsUsing LD to Infer Population History
The extent of linkage disequilibrium (LD) is influenced
by natural selection, mutation and recombination rates,
and population size. Our current understanding of the
response of LD to changes in population size is rather
crude, affecting our ability to make inferences on the
basis of LD measures. Rogers looked in depth at the
effects of changes in population size on LD measuresand found different signatures in the LD curves when
a population declines or grows and when it expands
after a period of equilibrium versus after a temporary
decline in size. Comparison of these curves to data
from a European population suggests a history of popu-
lation growth.
Rogers. (2014). Genetics. Published online June 6, 2014.
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